SEC Form 6-K filed by Immatics N.V.

SEC Form 6-K filed by Immatics N.V.

Recent Analyst Ratings for
$IMTX

$IMTX
Leadership Updates

$IMTX
Analyst Ratings

$IMTX
SEC Filings

Chat with this insight

Live Leadership Updates

Immatics Appoints Alise Reicin to Board of Directors

Memo Therapeutics AG appoints Paul Carter as Chairperson

Levicept Appoints Eliot Forster as CEO

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Piper Sandler initiated coverage on Immatics N.V. with a new price target

Cantor Fitzgerald initiated coverage on Immatics N.V.

Mizuho initiated coverage on Immatics N.V. with a new price target

8/13/24 7:07:01 AM ET

$IMTX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $IMTX alert in real time by email

6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule

13a-16

15d-16

of the Securities Exchange Act of 1934

August 13, 2024

Commission File Number:

001-39363

IMMATICS N.V.

Paul-Ehrlich-Straße 15

72076 Tübingen, Federal Republic of Germany

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form

20-F

or Form

40-F.

Form

20-F ☒ Form

40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM

6-K

On August 13, 2024, Immatics N.V. (the “Company”) issued an interim report for the three- and

six-month

periods ended June 30, 2024, which is attached hereto as Exhibit 99.1, and issued a press release announcing the second quarter 2024 financial results for the Company, which is attached hereto as Exhibit 99.2.

INCORPORATION BY REFERENCE

This Report on Form

6-K

(other than Exhibit 99.2

)

including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statements on Form

S-8

(Registration Nos.

333-249408,

333-265820

and

333-280935)

and the registration statements on Form

F-3

(Registration Nos.

333-240260

and

333-274218)

of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBITS


Exhibit Number		Description

99.1		Immatics N.V. interim report for the three- and six-month periods ended June 30, 2024.

99.2		Press release dated August 13, 2024.

101.INS		XBRL Taxonomy Extension Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this

report

to be signed on its behalf by the undersigned, thereunto duly authorized.

Get the next $IMTX alert in real time by email

Date

Price Target

Rating

Analyst

10/7/2024

$19.00

Overweight

Piper Sandler

11/2/2023

Overweight

Cantor Fitzgerald

3/31/2023

$12.00

Buy

Mizuho

3/24/2023

$16.00

Buy

Bryan Garnier

7/15/2021

$26.00 → $27.00

Outperform

SVB Leerink

IMMATICS N.V.

Date: August 13, 2024

/s/ Harpreet Singh

Harpreet Singh

Chief Executive Officer